Company Overview
Apyx Medical Corporation functions as an energy technology company dedicated to the design, development, manufacturing, and sale of electrosurgical equipment and medical devices for use in both domestic and international markets. The enterprise operates specifically within the healthcare sector, focusing on the medical devices industry, which implies a specialization in high-technology solutions for surgical and aesthetic procedures. The company's operational scale is defined by a market capitalization of $162.72 million and annual revenue of $52.84 million, supported by a workforce of 205 employees. These valuation and revenue figures indicate that the company maintains a mid-market position, balancing the need for capital investment in research and development against the constraints of a relatively small market capitalization.
Financial Health
The company reported revenue of $52.84 million for the trailing twelve months, yet it recorded a net income of -$11,211,000 and an EBITDA of -$5,791,000, revealing a significant divergence between top-line growth and profitability. This substantial gap between revenue and net income suggests that the cost structure includes heavy fixed costs or non-operating expenses that significantly erode bottom-line earnings before interest and taxes. Furthermore, the free cash flow stands at -$7,105,875, indicating that the company is currently burning cash rather than generating liquidity, which limits its financial flexibility for discretionary spending or debt reduction. Profitability analysis highlights a gross margin of 62.5%, which demonstrates efficient production costs, contrasted by an operating margin of 0.1% and a profit margin of -21.2%, signaling that overhead and other expenses are consuming nearly all operating profit. The balance sheet presents a leveraged profile with cash holdings of $31.74 million offset by total debt of $39.34 million, resulting in a debt-to-equity ratio of 265.25. Despite the net debt position, the current ratio of 5.00 indicates robust short-term liquidity, suggesting the company possesses ample current assets to cover its immediate liabilities. Return on equity is calculated at -76.1% and return on assets at -6.1%, metrics that reveal management is currently unable to generate returns on the capital invested in the business.
Valuation Assessment
Valuation metrics for Apyx Medical Corporation reflect a lack of traditional profitability benchmarks, with a P/E ratio (TTM) listed as N/A and a forward P/E of -13.79. The absence of a trailing P/E ratio combined with a negative forward P/E implies that the market is pricing the stock based on future expectations of earnings turnaround rather than historical performance. The price-to-book ratio is 11.18, indicating that the market values the company at a significant premium relative to its book value, likely due to the intangible value of its intellectual property and growth potential. Alternative valuation measures include a price-to-sales ratio of 3.08 and an EV/EBITDA of -29.46, which suggest the market is willing to pay a high multiple for revenue growth despite the current negative earnings multiple. The stock has traded between a 52-week low of $0.76 and a 52-week high of $4.50, and while the exact current price is not listed in the provided facts, the forward P/E metric implies the market is anticipating a shift in earnings trajectory. The beta value is 1.66, which indicates that the stock exhibits higher volatility relative to the broader market, moving more sharply than the average equity in response to market fluctuations.
Growth & Income
Revenue growth for the year-over-year period is 34.7%, while earnings growth is N/A due to the company's current unprofitable status. The inability to calculate earnings growth relative to revenue growth implies that the expansion of sales is not yet translating into proportional earnings increases, a common characteristic in capital-intensive medical device firms during scaling phases. As a non-dividend payer, the company maintains a dividend yield of N/A and a payout ratio of 0.0%, confirming that the firm reinvests all available earnings back into operations, research, and development rather than distributing income to shareholders. This reinvestment strategy supports the high revenue growth rate but necessitates the generation of positive cash flows to eventually support shareholder returns. The overall growth and income profile is characterized by strong top-line expansion coupled with a complete absence of current income distribution, reflecting a classic growth-stage capital structure.